期刊
TOXINS
卷 9, 期 2, 页码 -出版社
MDPI
DOI: 10.3390/toxins9020044
关键词
Shiga toxin; Stx1; Stx2; hemolytic uremic syndrome; inhibitors; chloroquine; fluorodeoxyglucose; Mn2+
资金
- Norwegian Cancer Society
- Research Council of Norway through its Centers of Excellence funding scheme [179571]
- South-Eastern Norway Regional Health Authority
Shiga toxins consist of an A-moiety and five B-moieties able to bind the neutral glycosphingolipid globotriaosylceramide (Gb3) on the cell surface. To intoxicate cells efficiently, the toxin A-moiety has to be cleaved by furin and transported retrogradely to the Golgi apparatus and to the endoplasmic reticulum. The enzymatically active part of the A-moiety is then translocated to the cytosol, where it inhibits protein synthesis and in some cell types induces apoptosis. Protection of cells can be provided either by inhibiting binding of the toxin to cells or by interfering with any of the subsequent steps required for its toxic effect. In this article we provide a brief overview of the interaction of Shiga toxins with cells, describe some compounds and conditions found to protect cells against Shiga toxins, and discuss whether they might also provide protection in animals and humans.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据